---
figid: PMC8124242__jcm-10-01992-g002
figtitle: 'Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative
  LDL and Potential Therapeutic Strategies'
organisms:
- NA
pmcid: PMC8124242
filename: jcm-10-01992-g002.jpg
figlink: /pmc/articles/PMC8124242/figure/jcm-10-01992-f002/
number: F2
caption: 'A potential therapeutic strategy for the targeting L5/LDL(−) and LOX-1 pathway
  in patients with AIRDs. Major therapeutic strategies include modifications of the
  traditional CVD risk factors; control of AIRD activity; and the use of lipid-lowering
  agents, cytokine-targeting agents, and LOX-1-targeting therapy. CVD: cardiovascular
  disease; LDL: low-density lipoprotein; HCQ: hydroxychloroquine; DMARDs: disease-modifying
  anti-rheumatic drugs; PCSK9: proprotein convertase subtilisin/kexin type 9; miRNA:
  microRNA; NF-kB: nuclear factor-kB; IL-1β: interleukin 1β.'
papertitle: 'Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative
  LDL and Potential Therapeutic Strategies.'
reftext: Der-Yuan Chen, et al. J Clin Med. 2021 May;10(9):1992.
year: '2021'
doi: 10.3390/jcm10091992
journal_title: Journal of Clinical Medicine
journal_nlm_ta: J Clin Med
publisher_name: MDPI
keywords: electronegative LDL | L5 | atherosclerotic cardiovascular disease (ASCVD)
  | autoimmune rheumatic diseases (AIRDs) | lectin-like oxidized low-density lipoprotein
  receptor 1 (LOX-1) | interleukin 1β (IL-1β)
automl_pathway: 0.785863
figid_alias: PMC8124242__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
- Danio rerio
redirect_from: /figures/PMC8124242__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8124242__jcm-10-01992-g002.html
  '@type': Dataset
  description: 'A potential therapeutic strategy for the targeting L5/LDL(−) and LOX-1
    pathway in patients with AIRDs. Major therapeutic strategies include modifications
    of the traditional CVD risk factors; control of AIRD activity; and the use of
    lipid-lowering agents, cytokine-targeting agents, and LOX-1-targeting therapy.
    CVD: cardiovascular disease; LDL: low-density lipoprotein; HCQ: hydroxychloroquine;
    DMARDs: disease-modifying anti-rheumatic drugs; PCSK9: proprotein convertase subtilisin/kexin
    type 9; miRNA: microRNA; NF-kB: nuclear factor-kB; IL-1β: interleukin 1β.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - cv-d
  - hi
  - Dif
  - dl
  - Rel
  - modSP
  - Rx
  - IL18
  - MIRLET7G
  - NFKB1
  - IL1B
  - OLR1
  - PCSK9
  - il1b
  - kita
  - ngfra
  - pcsk9
---
